Vir Biotechnology (VIR) AI Stock Analysis

• Market Cap: $714.03M
• Dividend Yield: N/A
• Average Volume (3M): 1.40M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.81
• Revenue Growth: -75.91%
• EPS Growth: -12.11%
• Country: US
• Employees: 408
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -0.80
• Shares Outstanding: 138,916,430
• 10 Day Avg. Volume: 2,142,979
• 30 Day Avg. Volume: 1,401,696
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.15
• Enterprise Value/Revenue: 6.35
• Enterprise Value/Gross Profit: 6.64
• Enterprise Value/Ebitda: -0.18
• 1Y Price Target: $16.29
• Price Target Upside: 209.11% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 55 Neutral
• Price Target: $5.50 ▲(4.36% Upside)

Vir Biotechnology's overall stock score reflects significant financial challenges, particularly in profitability and cash flow management. Despite positive developments in their ECLIPSE program and a strong cash position, the negative valuation metrics and ongoing net losses weigh heavily on the score. Technical indicators suggest moderate strength, but the stock remains below key long-term averages.

Positive Factors

Financial Stability

Vir ended 2Q25 with approximately $892M in cash and investments, providing financial stability and runway into mid-2027.

Hepatitis Delta Virus Program

The ECLIPSE program for chronic hepatitis delta is enrolling across all three registrational studies, marking a critical advancement for Vir’s lead infectious disease franchise.

Oncology Pipeline

Vir's oncology pipeline is advancing significantly with multiple active clinical programs supported by proprietary dual-masking technology.

Negative Factors

Market Perception

Minimal value seems to be attributed to T-cell engager oncology programs despite initial proof-of-concept data, suggesting an undervaluation.

Oncology Program Risks

VIR-5500 may fail to produce competitive data.

Stock Performance

The stock has traded down 40% year-to-date, attributed to a lack of catalyst flow and concerns on cash burn.

Vir Biotechnology Business Overview & Revenue Model

Company Description

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

How the Company Makes Money

Vir Biotechnology generates revenue primarily through the development and commercialization of its therapeutic products. This includes income from partnerships and collaborations with larger pharmaceutical companies, which often provide upfront payments, milestone payments, and royalties on sales. The company has entered into significant agreements aimed at accelerating the development and distribution of its therapies, particularly in response to public health needs, such as its collaboration with GlaxoSmithKline for the development of COVID-19 treatments. Additionally, government contracts and grants related to pandemic response initiatives can contribute to revenue, alongside potential market sales of approved therapies once they reach commercialization.

Vir Biotechnology Financial Statement Overview

Summary

Vir Biotechnology faces significant financial challenges, particularly in terms of profitability and cash flow management. Despite a strong gross profit margin and low leverage, negative revenue growth and substantial operating losses pose risks. The balance sheet remains relatively stable, but the company needs to address its profitability issues to improve its financial health.

Income Statement

Vir Biotechnology's income statement shows significant challenges. The company has experienced negative revenue growth in recent periods, with a TTM revenue decline of 10.05%. Profitability metrics are concerning, with a negative net profit margin of -33.02% and EBIT margin of -35.87% in the TTM. Despite a strong gross profit margin of 95.53%, the company struggles with high operating losses.

Balance Sheet

The balance sheet reflects moderate stability with a low debt-to-equity ratio of 0.10 in the TTM, indicating low leverage. However, the return on equity is negative at -50.22%, highlighting profitability issues. The equity ratio is not explicitly calculated, but the company maintains a substantial equity base relative to its assets.

Cash Flow

Cash flow analysis reveals a challenging situation with negative operating cash flow and free cash flow in the TTM. However, the free cash flow to net income ratio is slightly positive at 1.02, suggesting some efficiency in cash management despite losses. Free cash flow growth is positive at 10.48%, indicating some improvement.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.67M	74.20M	86.18M	1.58B	1.09B	67.25M
Gross Profit	15.92M	73.36M	83.42M	1.43B	1.02B	-234.33M
EBITDA	-584.86M	-537.61M	-664.85M	833.07M	420.75M	-289.80M
Net Income	-550.23M	-521.96M	-615.06M	515.84M	528.58M	-298.67M
Balance Sheet
Total Assets	1.19B	1.40B	1.92B	2.80B	1.95B	918.76M
Cash, Cash Equivalents and Short-Term Investments	686.97M	990.38M	1.52B	2.40B	708.14M	736.86M
Total Debt	93.41M	97.89M	124.54M	127.97M	133.56M	66.56M
Total Liabilities	245.06M	248.43M	328.82M	724.13M	522.42M	201.91M
Stockholders Equity	947.47M	1.15B	1.59B	2.08B	1.43B	716.85M
Cash Flow
Free Cash Flow	-466.38M	-453.65M	-800.36M	1.60B	-69.41M	-197.49M
Operating Cash Flow	-457.45M	-446.35M	-778.78M	1.66B	-47.59M	-190.94M
Investing Cash Flow	442.61M	499.37M	164.63M	-1.19B	-140.81M	-9.86M
Financing Cash Flow	3.94M	4.39M	7.48M	34.76M	100.33M	529.47M

Vir Biotechnology Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.27
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VIR, the sentiment is Positive. The current price of 5.27 is above the 20-day moving average (MA) of 4.68, above the 50-day MA of 5.09, and below the 200-day MA of 6.71, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 57.10 is Neutral, neither overbought nor oversold. The STOCH value of 65.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VIR.

Vir Biotechnology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIR	55 Neutral	$714.03M	―	-46.22%	―	-75.91%	-12.11%
NTLA	55 Neutral	$1.25B	―	-56.95%	―	14.99%	14.42%
RCUS	54 Neutral	$1.23B	―	-50.34%	―	6.07%	-2.28%
Sector *	51 Neutral	$7.92B	-0.43	-41.67%	2.21%	22.29%	-1.85%
NRIX	47 Neutral	$697.22M	―	-50.67%	―	41.86%	10.48%
SYRE	43 Neutral	$1.03B	2.31	-41.00%	―	―	-429.68%
PHVS	42 Neutral	$1.41B	―	-63.96%	―	―	-36.92%

Vir Biotechnology Corporate Events

Vir Biotechnology Begins Phase 1 Trial for VIR-5525

On July 24, 2025, Vir Biotechnology announced the dosing of the first patient in its Phase 1 clinical trial for VIR-5525, a dual-masked T-cell engager targeting EGFR for the treatment of solid tumors. This trial aims to evaluate the safety and efficacy of VIR-5525, both as a standalone treatment and in combination with pembrolizumab, for various EGFR-expressing tumors. The initiation of this trial triggers a $75 million milestone payment from Sanofi due upon VIR-5525 achieving “first in human dosing.” This reflects the company’s strategic progress in oncology and its commitment to addressing unmet needs in cancer treatment.

Vir Biotechnology Begins Phase 1 Trial for VIR-5525

On July 24, 2025, Vir Biotechnology announced the dosing of the first patient in its Phase 1 clinical trial for VIR-5525, a dual-masked T-cell engager targeting EGFR for the treatment of solid tumors. This trial aims to evaluate the safety and efficacy of VIR-5525, both as a standalone treatment and in combination with pembrolizumab, for various EGFR-expressing tumors. The initiation of this trial triggers a $75 million milestone payment from Sanofi due upon VIR-5525 achieving “first in human dosing.” This reflects the company’s strategic progress in oncology and its commitment to addressing unmet needs in cancer treatment.